CN114099620A

CN114099620A - Selenium wine for protecting liver and preventing liver diseases

Info

Publication number: CN114099620A
Application number: CN202111330176.XA
Authority: CN
Inventors: 罗杰; 罗懿睿; 汤曼
Original assignee: Sichuan Zhongchang Kanglv Industrial Development Co ltd
Current assignee: Sichuan Zhongchang Kanglv Industrial Development Co ltd
Priority date: 2021-11-10
Filing date: 2021-11-10
Publication date: 2022-03-01

Abstract

The invention relates to the technical field of selenium wine, and discloses a selenium wine for protecting liver and preventing liver diseases, which comprises the following components: the selenium-enriched capsella bursa-pastoris wine base, the selenium-enriched capsella bursa-pastoris plant crushed powder, a new food raw material, a medicinal plant, a medicinal animal and a medicinal animal product, wherein each component comprises the following components in parts by weight: 200-250 parts of wine base, 20-25 parts of selenium-rich capsella bursa-pastoris plant crushed powder, 10-15 parts of new food raw materials, 10-15 parts of medicinal plants, 50-75 parts of medicinal animals and 5-10 parts of medicinal animal products.

Description

Selenium wine for protecting liver and preventing liver diseases

Technical Field

The invention relates to the technical field of selenium wine, in particular to selenium wine for protecting liver and preventing liver diseases.

Background

Selenium is a mineral trace element, plays a special physiological function and restricts the occurrence of certain diseases in the life of a human body or an animal, and most of selenium supplement of the human body is taken in through the outside, such as selenium wine or selenium beverage, but the existing selenium wine has no functions of protecting the liver and repairing liver injury, and the existing selenium wine has no function of reducing blood uric acid, so that gout is avoided. Therefore, the person skilled in the art provides a selenium wine for protecting liver and preventing liver diseases to solve the problems mentioned in the background art.

Disclosure of Invention

The invention aims to provide selenium wine for protecting liver and preventing liver diseases, so as to solve the problems in the background technology.

In order to achieve the purpose, the invention provides the following technical scheme:

a selenium wine for protecting liver and preventing liver diseases comprises the following components: the selenium-enriched capsella bursa-pastoris wine base, the selenium-enriched capsella bursa-pastoris plant crushed powder, a new food raw material, a medicinal plant, a medicinal animal and a medicinal animal product, wherein each component comprises the following components in parts by weight: 200-250 parts of wine base, 20-25 parts of selenium-rich shepherd's purse plant crushed powder, 10-15 parts of new food raw material, 10-15 parts of medicinal plant, 50-75 parts of medicinal animal and 5-10 parts of medicinal animal product.

As a still further scheme of the invention: the wine base is composed of distilled wine, the new food raw materials are composed of phytosterol, saussurea involucrate cultures, moringa leaves, assai fruits, small blackberries and lindera roots, and the mass ratio of the phytosterol to the saussurea involucrate cultures to the moringa leaves to the assai fruits to the small blackberries to the lindera roots is 1:1:2:3:2: 2.

As a still further scheme of the invention: the medicinal plants comprise radix astragali, lalang grass rhizome, herba Cichorii, herba Eleocharitis Oligocarpae, fructus Phyllanthi, radix Arctii and radix fici Simplicissimae, wherein the radix astragali, lalang grass rhizome, herba Cichorii, herba Eleocharitis Elegantis, fructus Phyllanthi, radix Arctii and radix fici Simplicissimae are in mass ratio: 2:2:1:1:2:3:1.

As a still further scheme of the invention: the medicinal animals comprise dried Zaocys dhumnades.

As a still further scheme of the invention: the medicinal animal product consists of silkworm excrement and silkworm chrysalis, and the mass ratio of the silkworm excrement to the silkworm chrysalis is 1: 2.

A selenium wine for protecting liver and preventing liver diseases is prepared by the following steps:

s1, preparing 200-250 parts of wine base, 20-25 parts of selenium-rich capsella bursa-pastoris plant crushed powder, phytosterol and saussurea involucrate culture in advance, putting 200-250 parts of wine base, 20-25 parts of selenium-rich capsella bursa-pastoris plant crushed powder, phytosterol and saussurea involucrate culture into a medicine powder mixer for stirring, and taking out for later use after stirring is completed;

s2, cleaning and drying the moringa leaves and the lindera roots, cleaning the moringa leaves and the lindera roots, drying in the shade, coarse crushing to obtain ultrafine powder, uniformly mixing moringa leaf powder and lindera roots leaf powder with yeast according to a certain proportion, performing solid saccharification and fermentation to obtain a base material, performing aseptic and constant temperature fermentation for 5-10 days, and cleaning the assai fruits and the small hei for later use;

s3, cleaning radix astragali, lalang grass rhizome, chicory, herba auriculati-judae roxburghii, emblic leafflower fruit, burdock root and hispid fig, drying in the air, performing freeze-drying treatment by using a freeze-dryer, and cutting into 2-3 cm small sections for later use after freeze-drying;

s4, putting the base material, the assai fruit, the small black medicine and the spare material in the S3 step in the S2 step into the spare material in the S1 step, then putting the silkworm excrement and the silkworm chrysalis into the spare material in the S1 step, fully stirring to obtain a mixed material, soaking for 45-60 days, filtering the mixed material, sterilizing after filtering, and continuously soaking the dried zaocys dhumnade into the filtered and sterilized mixed material to obtain the finished selenium wine.

As a still further scheme of the invention: the mesh number of the ultrafine powder in the S2 is 250-300, the ratio of the moringa leaf powder, the lindera aggregate leaf powder and the yeast is 50-200: 1, and the constant temperature is 13-18 ℃.

Compared with the prior art, the invention has the beneficial effects that:

1. the phytosterol, the moringa leaves, the assai fruit, the astragalus membranaceus, the lalang grass rhizome, the chicory and the auricularia auricula-judae alvine root bark have a liver protection effect, and when the phytosterol, the moringa leaves, the assai fruit, the astragalus membranaceus, the lalang grass rhizome, the chicory and the auricularia auricula-judae alvine root bark are mixed together for use, the liver protection effect is greatly improved, the reduction of liver glycogen can be prevented, the liver damage can be resisted, damaged liver cells can be repaired, and the function of protecting the liver can be realized.

2. The radix linderae, the lindera aggregate leaves, the emblic leafflower fruits and the hispid fig have the functions of tonifying the kidney and the spleen, and are mixed for use, so that the purine metabolism efficiency is improved, the content of uric acid in blood is reduced, and the gout caused by hyperuricemia is avoided.

Detailed Description

In the embodiment of the invention, the selenium wine for protecting liver and preventing liver diseases comprises the following components: the selenium-enriched capsella bursa-pastoris wine base, the selenium-enriched capsella bursa-pastoris plant crushed powder, a new food raw material, a medicinal plant, a medicinal animal and a medicinal animal product, wherein each component comprises the following components in parts by weight: 200-250 parts of wine base, 20-25 parts of selenium-rich shepherd's purse plant crushed powder, 10-15 parts of new food raw material, 10-15 parts of medicinal plant, 50-75 parts of medicinal animal and 5-10 parts of medicinal animal product.

Preferably, the wine base is composed of distilled wine, the new food raw material is composed of phytosterol, saussurea involucrate culture, horseradish tree leaves, assai fruit, small blackberry and lindera root leaves, and the mass ratio of the phytosterol, the saussurea involucrate culture, the horseradish tree leaves, the assai fruit, the small blackberry and the lindera root leaves is 1:1:2:3:2: 2.

Preferably, the medicinal plants comprise astragalus, cogongrass rhizome, chicory, auriculate swallowwort root, emblic leafflower fruit, burdock root and hispid fig root, and the astragalus, the cogongrass rhizome, the chicory, the auriculate swallowwort root, the emblic leafflower fruit, the burdock root and the hispid fig root are in the following mass ratio: 2:2:1:1:2:3:1.

Preferably, the medicinal animal is composed of dried Zaocys dhumnades.

Preferably, the mesh number of the ultrafine powder in the S2 is 250-300, the ratio of the moringa leaf powder to the lindera aggregate leaf powder to the yeast is 50-200: 1, and the constant temperature is 13-18 ℃.

To better illustrate the technical effect of the present invention, it is illustrated by the following experiments:

selecting a selenium-rich biological wine (No. CN107118913A) disclosed in Chinese patent as a first comparative example;

selecting selenium-rich health wine disclosed in Chinese patent and its production method (No. CN101735918B) as comparative example II;

selecting a preparation method (No. CN1134978A) of selenium-rich cordyceps sinensis tonic wine disclosed by Chinese patent as a third comparative example;

the invention was chosen as the example.

The method comprises the following steps of firstly, selecting five groups of mice with good health conditions for experiment, and dividing the mice into a group A, a group B, a group C, a group D and a group E, wherein each group comprises ten mice, the group A is used for a first comparative example, the group B is used for a second comparative example, the group C is used for a third comparative example, and the group D is used for the example; preparing a carbon tetrachloride solution which can cause chronic liver injury, injecting 5ml of carbon tetrachloride solution into each mouse in the A group, the B group, the C group, the D group and the E group every day and normally feeding the mice, continuously injecting the mice for fourteen days, drawing blood to test and detect the value of glutamic-pyruvic transaminase, wherein the value of the glutamic-pyruvic transaminase shows the good or bad liver function, and the normal range of the glutamic-pyruvic transaminase of the mice is as follows: 25-74 IU/L, wherein the following table shows the glutamic-pyruvic transaminase values of mice in groups A, B, C, D and E;

group A	92	87	97	96	95	94	90	82	89	102
											Group B	90	83	87	96	101	91	94	107	90	82
Group C	99	82	110	96	88	87	96	83	103	93
											Group D	94	96	83	97	82	103	89	87	105	90
Group E	98	105	82	104	87	96	87	83	102	91

From the above table, the values of the glutamic pyruvic transaminase in group A exceed 74IU/L and the average value is 92.4, the values of the glutamic pyruvic transaminase in group B exceed 74IU/L and the average value is 92.1, the values of the glutamic pyruvic transaminase in group C exceed 74IU/L and the average value is 93.7, the values of the glutamic pyruvic transaminase in group D exceed 74IU/L and the average value is 92.6, and the values of the glutamic pyruvic transaminase in group E exceed 74IU/L and the average value is 93.5;

then, 5ml of the first control example was injected daily to each mouse in the group A, 5ml of the second control example was injected daily to each mouse in the group B, 5ml of the third control example was injected daily to each mouse in the group C, 5ml of the example was injected daily to each mouse in the group D, the mice in the group E were not treated, and after fourteen days of normal feeding, blood was drawn for assaying the glutamic-pyruvic transaminase value, and the following table was obtained:

group A	75	75	69	76	80	77	80	71	77	89
											Group B	79	80	80	82	86	78	83	91	79	71
Group C	85	73	89	84	79	75	74	72	87	81
											Group D	45	50	52	65	43	49	49	55	68	56
Group E	90	95	76	96	78	80	77	76	97	83

From the above table, it can be seen that four of the mice in group a had no glutamate pyruvate transaminase values exceeding 75IU/L, the remaining six remained over 75IU/L, and the average value of group a was 76.9, one of the mice in group B had no glutamate pyruvate transaminase values exceeding 75IU/L, the remaining nine remained over 75IU/L, and the average value of group B was 80.9, four of the mice in group C had no glutamate pyruvate transaminase values exceeding 75IU/L, the remaining six remained over 75IU/L, and the average value of group C was 79.9, the glutamate pyruvate transaminase values of the mice in group D did not exceed 75IU/L, and the average value of group D was 53.2, the glutamate pyruvate transaminase values of the mice in group E exceeded 75IU/L, and the average value of 84.8;

from this it can be analytically derived: the phytosterol, the moringa leaves, the assai fruit, the astragalus membranaceus, the lalang grass rhizome, the chicory and the auricularia auricula-judae are mixed together for use, so that the liver protection effect is greatly improved, the reduction of liver glycogen can be prevented, the liver damage can be resisted, and damaged liver cells can be repaired.

Selecting five groups of mice with good health conditions for experiment, wherein the mice are divided into ten groups, namely F group, G group, H group, I group and J group, the F group is used for the first comparative example, the G group is used for the second comparative example, the H group is used for the third comparative example, and the I group is used for the example; preparing potassium oxonate combined yeast solution, wherein the potassium oxonate combined yeast solution can cause blood uric acid to rise, so that gout is suffered, injecting 3ml of potassium oxonate combined yeast solution into each of mice in groups F, G, H, I and J every day, normally feeding, continuously injecting fourteen days, drawing blood, testing and detecting the value of blood uric acid, wherein the value of blood uric acid shows whether hyperuricemia or gout can be caused, and the normal uric acid range of the mice is as follows: 178-398 umol/L, the table below is the uric acid values of mice in groups F, G, H, I and J;

from the above table, the blood uric acid values of the group F are all over 398umol/L and the average value is 495.8umol/L, the blood uric acid values of the group G are all over 398umol/L and the average value is 496.7umol/L, the blood uric acid values of the group H are all over 74IU/L and the average value is 497.9umol/L, the blood uric acid values of the group I are all over 398umol/L and the average value is 492.2umol/L, the blood uric acid values of the group J are all over 398umol/L and the average value is 496.1 umol/L;

then, 5ml of the first control example was injected daily to each mouse in the group F, 5ml of the second control example was injected daily to each mouse in the group G, 5ml of the third control example was injected daily to each mouse in the group H, 5ml of the example was injected daily to each mouse in the group I, the mice in the group J were not treated, and blood was drawn for assay to detect the value of glutamic-pyruvic transaminase fourteen days after normal feeding, and the following table was obtained:

group F	418	428	428	463	433	403	470	423	448	437
											Group G	432	480	441	429	434	416	459	435	420	431
Group H	422	430	492	439	405	440	429	457	415	430
											Group I	355	310	322	312	343	321	300	297	331	319
J group	443	464	493	487	424	516	523	460	455	465

From the above table, it can be found that the uric acid values of the mice in the group F are all reduced to a certain extent, but all are still over 398umol/L, and the average value is 435.1umol/L, the uric acid values of the mice in the group G are all reduced to a certain extent, but all are still over 398umol/L, and the average value is 437.7umol/L, the uric acid values of the mice in the group H are all reduced to a certain extent, but all are over 398umol/L, and the average value is 435.9umol/L, the uric acid values of the mice in the group I are all greatly reduced and are within the normal range, and the average value is 321umol/L, the uric acid values of the mice in the group J are all reduced to a small extent, but all are over 398umol/L, and the average value is 473 umol/L;

from this it can be analytically derived: according to the invention, the small radix linderae, the lindera aggregate leaf, the emblic leafflower fruit and the hispid fig have the functions of tonifying the kidney and the spleen, and the purine metabolism efficiency is improved, so that the content of uric acid in blood is reduced, and gout caused by hyperuricemia is avoided.

The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention are equivalent to or changed within the technical scope of the present invention.

Claims

1. A selenium wine for protecting liver and preventing liver diseases comprises the following components: the selenium-enriched capsella bursa-pastoris wine base, the selenium-enriched capsella bursa-pastoris plant powder, a new food raw material, a medicinal plant, a medicinal animal and a medicinal animal product, and is characterized in that each component comprises the following components in parts by weight: 200-250 parts of wine base, 20-25 parts of selenium-rich shepherd's purse plant crushed powder, 10-15 parts of new food raw material, 10-15 parts of medicinal plant, 50-75 parts of medicinal animal and 5-10 parts of medicinal animal product.

2. The selenium wine for protecting liver and preventing liver diseases according to claim 1, wherein the wine base is composed of distilled wine, the new food raw material is composed of phytosterol, saussurea involucrate culture, moringa leaves, assai fruit, radix aconiti nigra and radix linderae leaves, and the mass ratio of the phytosterol, the saussurea involucrate culture, the moringa leaves, the assai fruit, the radix aconiti nigra and the radix linderae leaves is 1:1:2:3:2: 2.

3. The selenium wine for protecting liver and preventing liver diseases according to claim 1, wherein the medicinal plants comprise astragalus, cogongrass rhizome, chicory, auriculate swallowwort root, emblic leafflower fruit, burdock root and hispid fig root, and the astragalus, the cogongrass rhizome, the chicory, the auriculate swallowwort root, the emblic leafflower fruit, the burdock root and the hispid fig root are mixed according to the mass ratio: 2:2:1:1:2:3:1.

4. The selenium wine of claim 1, wherein the animal comprises dried Zaocys dhumnades.

5. The selenium wine for protecting liver and preventing liver diseases according to claim 1, wherein the medicinal animal product comprises silkworm excrement and silkworm chrysalis, and the mass ratio of the silkworm excrement to the silkworm chrysalis is 1: 2.

6. The selenium wine for protecting liver and preventing liver diseases according to claim 1, wherein the preparation method comprises the following steps:

7. The selenium wine for protecting liver and preventing liver diseases according to claim 6, wherein the mesh number of the ultrafine powder in S2 is 250-300, the ratio of the moringa leaf powder, the lindera aggregate leaf powder and the yeast is 50-200: 1, and the constant temperature is 13-18 ℃.